A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

Allison Rosenthal, Amylou C. Dueck, Stephen Ansell, Katherine Gano, Christopher Conley, Grzegorz S. Nowakowski, John Camoriano, Jose F. Leis, Joseph R. Mikhael, A. Keith Stewart, David Inwards, David Dingli, Shaji Kumar, Pierre Noel, Morie Gertz, Luis Porrata, Stephen Russell, Joseph Colgan, Rafael Fonseca, Thomas M. HabermannPrashant Kapoor, Francis Buadi, Nelson Leung, Rodger Tiedemann, Thomas E. Witzig, Craig Reeder

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences